We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Consensus and Guidelines · August 17, 2020

Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies

European Journal of Heart Failure


Additional Info

European Journal of Heart Failure
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration With the International Cardio-Oncology Society
Eur. J. Heart Fail 2020 May 28;[EPub Ahead of Print], AR Lyon, S Dent, S Stanway, H Earl, C Brezden-Masley, A Cohen-Solal, CG Tocchetti, JJ Moslehi, JD Groarke, J Bergler-Klein, V Khoo, LL Tan, MS Anker, S von Haehling, C Maack, R Pudil, A Barac, P Thavendiranathan, B Ky, TG Neilan, Y Belenkov, SD Rosen, Z Iakobishvili, AL Sverdlov, LA Hajjar, AVS Macedo, C Manisty, F Ciardiello, D Farmakis, RA de Boer, H Skouri, TM Suter, D Cardinale, RM Witteles, MG Fradley, J Herrmann, RF Cornell, A Wechelaker, MJ Mauro, D Milojkovic, H de Lavallade, F Ruschitzka, AJS Coats, PM Seferovic, O Chioncel, T Thum, J Bauersachs, MS Andres, DJ Wright, T López-Fernández, C Plummer, D Lenihan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading